US · Healthcare · Drug Manufacturers - General
EPS came in at 2.62 against a street estimate of 2.06 — a beat of 27.2%.
Analysts rate Biogen Inc a buy (25 buy, 10 hold, 1 sell out of 36) with an average price target of $264.82.
CONFIDENT Biogen reported strong Q3 growth, led by growth products and Apellis assets, raised the lower EPS-guidance bound, and highlighted upcoming lupus and kidney-disease catalysts. Q3 FY26 U.S. growth included early LEQVI iClick uptake and strong SKYCLARYS demand; European TYSABRI was stable, while broader geographic growth supported LEQVI and SYFOVRE. Analysts focused on lupus trial risk, AMR commercialization, SYFOVRE demand quality, high-dose SPINRAZA conversion, and capital allocation. Management emphasized trial-design controls, targeted launch preparation, and continued commercial momentum. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 12.32% |
| BlackRock Inc | 10.81% |
| PRIMECAP Management Company | 10.25% |
| Vanguard Capital Management, LLC | 6.53% |
| State Street Corp | 4.97% |
| Vanguard Portfolio Management, LLC | 4.47% |
| Geode Capital Management, LLC | 3.01% |
| Wellington Management Company LLP | 2.11% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $2,804.1 million, up from $2,534.7 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $2.8 billion, up 11% year over year, or 10% at constant currency. • Growth Portfolio revenue was $1.26 | 2026-10-28 |
| Quarterly report · Q2 2026 BIOGEN INC. - Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $5,213.8 million vs. $5,076.5 million in prior year (2.7% incre | 2026-07-29 |
| Results announced · Q3 2026 BIOGEN Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue $2.7 billion, up 3% year-over-year (2% at constant currency) • GAAP diluted EPS $0. | 2026-07-29 |
| Results announced · Q3 2026 BIOGEN INC. (BIIB) – FORM 8-K SUMMARY HEADLINE NUMBERS • Q2 2026: Acquired in-process R&D, upfront and milestone expenses of approximately $164 mill | 2026-07-01 |
| Shareholder vote results · Q2 2026 BIOGEN INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 9, 2026 • Total votes cast across all proposals: approximatel | 2026-06-10 |
| Material agreement · Q2 2026 BIOGEN INC. - 8-K FILING SUMMARY (May 14, 2026) HEADLINE NUMBERS • Acquisition price: Approximately $5.3 billion in aggregate consideration (excludi | 2026-05-14 |
| Quarterly report · Q1 2026 BIOGEN INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Total Revenue: $2,477.8 million vs. Q1 2025: $2,431.0 million (+1.9% year-over-year) • | 2026-04-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquired in-process R&D expenses from research and development acquisition Biogen announced significant one-time charges related to research and development acquisitions and licensing deals. In Q2 2026, the company expects a $164 million pre-tax charge that will re | 2026-07-01 |
| Merger with Apellis Pharmaceuticals consummated Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026. This 8-K filing announces the merger's completion and provides references to financial documents. Key details: Bi | 2026-05-14 |
| Collaboration and license agreements with upfront and milestone payments Biogen announced that its Q1 2026 financial results will include a one-time charge of approximately $34 million ($0.19 per diluted share) related to acquired in-process research and developm | 2026-04-06 |
| Entered into Agreement and Plan of Merger with Apellis Pharmaceuticals Biogen Inc. announced on March 31, 2026, that it is acquiring Apellis Pharmaceuticals, Inc. through a tender offer and merger. Under the agreement, Biogen will pay Apellis shareholders $41.0 | 2026-03-31 |
| Acquired in-process R&D and upfront milestone expenses of $222 million Biogen announced that its fourth quarter 2025 results will include a $222 million pre-tax charge for acquired in-process research and development (IPR&D), upfront payments, and milestone exp | 2026-01-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biogen Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.